ArticlePloS one2014
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Beyond STMN1: stathmin-family control of microtubule dynamics and paclitaxel resistance in cancer.Frontiers in oncology · 2026Review
- The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors.Diagnostic pathology · 2024Article
- Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas.International journal of medical sciences · 2024Review
- LIM1 contributes to the malignant potential of endometrial cancer.Frontiers in oncology · 2023Article
- HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.Cell death & disease · 2022Article
- Stathmin dynamics modulate the activity of eribulin in breast cancer cells.Pharmacology research & perspectives · 2021Article
- STMN1 and MKI67 Are Upregulated in Uterine Leiomyosarcoma and Are Potential Biomarkers for its Diagnosis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.Current oncology (Toronto, Ont.) · 2019Observational
- The effect of downregulation of Stathmin gene on biological behaviors of U373 and U87-MG glioblastoma cells.Biological research · 2018Article
- Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.The journal of pathology. Clinical research · 2017Article
- Overexpression of stathmin plays a pivotal role in the metastasis of esophageal squamous cell carcinoma.Oncotarget · 2017Article
- High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.Gynecologic oncology · 2017Article
- High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.British journal of cancer · 2017Article
- Comparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines.Oncology letters · 2017Article
- Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.Journal of translational medicine · 2016Review
- miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1.Oncotarget · 2016Article
- Microtubule-Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy.Medicinal research reviews · 2016Review
- Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.Cancer gene therapy · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cell lines before and after stathmin knock-down. Subsequently we investigated the clinical response to paclitaxel containing chemotherapy in metastatic endometrial cancer in relation to stathmin protein level in tumors. Stathmin level was also determined in metastatic lesions, analyzing changes in biomarker status on disease progression. Knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel. In clinical samples, high stathmin level was demonstrated to be associated with poor response to paclitaxel containing chemotherapy and to reduced disease specific survival only in patients treated with such combination. Stathmin level increased significantly from primary to metastatic lesions. This study suggests, supported by both preclinical and clinical data, that stathmin could be a predictive biomarker for response to paclitaxel treatment in endometrial cancer. Re-assessment of stathmin level in metastatic lesions prior to treatment start may be relevant. Also, validation in a randomized clinical trial will be important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.